Serial dilutions of unfused albumin variants (0.034375.2 nM) or GLP-1 albumin fusions (0.031368.5 nM) (100 L/well), diluted in PBS/T/M (pH 5.5 or pH 7.4), were added for 1 h at room temperature
Large-scale human data: A 2023 study of nearly 30,000 patients found GLP-1 medicines were linked with fewer depressive symptoms, independent of weight loss
The pharmacology of these two long-acting GLP-1 analogs, in terms of improving glycemic control, reducing body weight and decreasing cardiovascular (CV) risk, is also reviewed, together with some novel biology
Researchers attribute this to a combination of reduced food intake mainly through delayed gastric emptying, appetite suppression, and increased energy expenditure, likely influenced by central and peripheral hormone signaling